stockrow
Friday 6 November 2026
Export FRNM’s income statement to Excel — free account
Freenome, Inc
FRNM Healthcare Diagnostics & Research
- EPS
- −115.2%
- Free cash flow
- +12.1%
Quarter to June 2026, against a year earlier
10.47
0.83
−7.35%
Follow FRNM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | 2 | 1 | (1) | (56.2%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | 2 | 1 | (1) | (56.2%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | 0.85 | 0.34 | (0.31) | (59.7%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.16) | (0.35) | (0.37) | +124.6% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.16) | (0.35) | (0.37) | +124.6% | ||||||
| Book value | — | — | — | — | — | — | — | — | (0.94) | (1.96) | (2.58) | +108.2% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 2 | 2 | +8.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | 0 | (1) | (1) | +144.5% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | 0 | (1) | (1) | +144.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 1 | (1) | (3) | n/m | |||||
| Net debt | — | — | — | — | — | — | — | — | (1) | (1) | 0 | (23.4%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (2) | (5) | (6) | +126.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | 0.92 | (0.86) | +0.9 pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (24.23) | 17.81 | (24.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Freenome, Inc vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NEO NeoGenomics, Inc. | $2.1B | — (loss-making) | — (loss-making) | +11.43% (above 0%: growing) | n/m | −3,724.21% (below 0%: shrinking) | 46.16% | (3.79%) | Compare |
| VCYT Veracyte, Inc. | $1.9B | 15.2× | 45.2× | +15.08% (above 0%: growing) | +62.50% (above 0%: growing) | −9.63% (below 0%: shrinking) | 70.58% | 10.92% | Compare |
| WGS GeneDx Holdings Corp. | $1.9B | — (loss-making) | — (loss-making) | +11.44% (above 0%: growing) | n/m | −585.59% (below 0%: shrinking) | 68.37% | (15.25%) | Compare |
| PSNL Personalis, Inc. | $1.7B | — (loss-making) | — (loss-making) | +76.59% (above 0%: growing) | n/m | −15.54% (below 0%: shrinking) | 25.67% | (138.76%) | Compare |
| OPK OPKO Health, Inc. | $1.3B | — (loss-making) | — (loss-making) | −56.87% (below 0%: shrinking) | n/m | −3.40% (below 0%: shrinking) | 64.30% | (48.02%) | Compare |
| FRNM Freenome, Inc | $1.1B | — (loss-making) | — | — | n/m | +12.06% (above 0%: growing) | — | 0.00% | |
| CSTL Castle Biosciences, Inc. | $1.0B | — (loss-making) | — (loss-making) | +23.90% (above 0%: growing) | n/m | +56.82% (above 0%: growing) | 76.75% | (2.65%) | Compare |
| MYGN Myriad Genetics, Inc. | $601.6M | — (loss-making) | — (loss-making) | −10.51% (below 0%: shrinking) | n/m | +43.90% (above 0%: growing) | 66.60% | (20.40%) | Compare |
| FLGT Fulgent Genetics, Inc. | $513.4M | — (loss-making) | — (loss-making) | +7.54% (above 0%: growing) | n/m | +2,058.74% (above 0%: growing) | 35.33% | (24.94%) | Compare |
| Median of peers | $1.5B | — | — | +11.44% | — | −6.51% | 65.45% | (17.82%) |
Pay and ownership Proxy statement filed 14 May 2026
Ownership
Directors and executive officers, together
22.10%
Perceptive Capital Solutions Holdings (our Sponsor)
21.30%
Adam Stone
21.30%
Michael Altman
21.30%
Commodore Capital LP
6.80%
ADAR1 Capital Management, LLC
6.80%
Venrock Healthcare Capital Partners III, L.P.
6.80%
RA Capital Management, L.P.
6.80%
RTW Investments, LP
6.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement